Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells-Reference-Cited by-同舟云学术

Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells

Published:2012-07 Issue:32 Volume:30 Page:4790-4799
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Wang Ce,Zhuang Yan,Zhang Yijuan,Luo Zichao,Gao Ningning,Li Ping,Pan Hong,Cai Lintao,Ma Yifan

Funder

National Natural Science Foundation of China

Shenzhen Basic Research Program

National Basic Research Program of China

Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies (GIRTF-LCHT)

Key Project of Science and Technology of Guangdong

“Hundred Talents Program” of Chinese Academy of Sciences

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference41 articles.

1. Promising particle-based vaccines in cancer therapy;Xiang;Expert Rev Vaccines,2008

2. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant;Longhi;J Exp Med,2009

3. Toll-like receptor 3 ligand and retinoic acid enhance germinal center formation and increase the tetanus toxoid vaccine response;Ma;Clin Vaccine Immunol,2009

4. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis;Durantez;Vaccine,2010

5. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C);Wick;Vaccine,2011

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine;European Journal of Pharmaceutics and Biopharmaceutics;2024-04

2. Toll-like receptor agonists as cancer vaccine adjuvants;Human Vaccines & Immunotherapeutics;2023-12-28

3. Heterogeneity of the tumor immune microenvironment and clinical interventions;Frontiers of Medicine;2023-08

4. A mini review for lipid-based nanovaccines: from their design to their applications;Journal of Liposome Research;2023-03-01

5. Delivery of Rna Drugs: Beyond the Liver, More than Vaccine;2023